We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

48 hedge funds and large institutions have $116M invested in VYNE Therapeutics in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

0.11% less ownership

Funds ownership: 0.98% → 0.86% (-0.11%)

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

2% less funds holding

Funds holding: 49 → 48 (-1)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

80% less capital invested

Capital invested by funds: $579M → $116M (-$463M)

Holders
48
Holders Change
-1
Holders Change %
-2.04%
% of All Funds
1.1%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
13
Increased
14
Reduced
11
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
DAFNA Capital Management
California
+$3.37M
2
Millennium Management
Millennium Management
New York
+$2.31M
3
NHAS
Novo Holdings A/S
Denmark
+$810K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$637K
5
SSA
Schonfeld Strategic Advisors
New York
+$539K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$16M
2
VMI
VHCP Management II
New York
-$12.8M
3
CAM
Cormorant Asset Management
Massachusetts
-$12.7M
4
Franklin Resources
Franklin Resources
California
-$7.52M
5
PA
Perceptive Advisors
New York
-$3.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$118K +$157K +202 New
Deutsche Bank
27
Deutsche Bank
Germany
$115K +$63.7K +82 +71%
Morgan Stanley
28
Morgan Stanley
New York
$111K -$7K -9 -5%
TA
29
Teachers Advisors
New York
$101K – – –
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
$96K +$128K +165 New
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$80K – – –
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$60K +$77.7K +100 +3,333%
AIG
33
American International Group
New York
$34K +$777 +1 +2%
New York State Common Retirement Fund
34
New York State Common Retirement Fund
New York
$28K – – –
Bank of America
35
Bank of America
North Carolina
$25K +$27.2K +35 +500%
PCM
36
Prelude Capital Management
New York
$16K +$21.8K +28 New
Citigroup
37
Citigroup
New York
$10K +$4.66K +6 +50%
Legal & General Group
38
Legal & General Group
United Kingdom
$9K – – –
TRCT
39
Tower Research Capital (TRC)
New York
$8K +$10.1K +13 New
UBS Group
40
UBS Group
Switzerland
$7K +$4.66K +6 +120%
Wells Fargo
41
Wells Fargo
California
$6K -$2.33K -3 -21%
Barclays
42
Barclays
United Kingdom
$5K -$7K -9 -50%
AIP
43
Ameritas Investment Partners
Nebraska
$4K – – –
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K -$52.9K -68 -96%
PNC Financial Services Group
45
PNC Financial Services Group
Pennsylvania
$2K +$2.33K +3 +300%
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
$1.91K -$10.1K -13 -81%
PIA
47
Piedmont Investment Advisors
North Carolina
$1K +$1.55K +2 New
DM
48
Deerfield Management
New York
– -$16M -5,927 Closed
VMI
49
VHCP Management II
New York
– -$12.8M -4,722 Closed
CAM
50
Cormorant Asset Management
Massachusetts
– -$12.7M -4,677 Closed
1
2
3

VYNE Hedge Fund Activity: Q2 2018 in Review

48 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q2 2018, worth a combined $116M — down 80% from $579M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of VYNE and 13 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 14 added.

The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $3.37M. The largest seller was Deerfield Management, exiting entirely with an estimated $16M sold.

  • 48 institutional investors held VYNE Therapeutics (VYNE) as of Q2 2018, down from 49 in Q1 2018.
  • Funds reported $116M of VYNE Therapeutics stock for Q2 2018, down 80% quarter-over-quarter.
  • 13 funds opened new VYNE Therapeutics positions in Q2 2018 and 14 closed out, a net change of -1 holder.
  • The largest VYNE Therapeutics buyer in Q2 2018 was DAFNA Capital Management, an estimated $3.37M added.
  • The largest VYNE Therapeutics seller in Q2 2018 was Deerfield Management, an estimated $16M sold.

Based on aggregated 13F filings for Q2 2018.